AstraZeneca PLC (AZN) | Statement of Financial Position, Liabilities and Stockholders' Equity
The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.
Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.
AstraZeneca PLC, Consolidated Statement of Financial Position, Liabilities and Stockholders' Equity
USD $ in millions
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current interest-bearing loans and borrowings | 901 | 1,990 | 125 | 1,926 | 993 | ||||||
| Trade payables | 2,449 | 2,155 | 2,257 | 2,316 | 1,940 | ||||||
| Value added and payroll taxes and social security | 231 | 343 | 323 | 342 | 371 | ||||||
| Rebates and chargebacks | 2,486 | 3,285 | 2,839 | 2,618 | 1,963 | ||||||
| Accruals | 3,200 | 2,474 | 2,297 | 2,373 | 1,878 | ||||||
| Other payables | 855 | 718 | 945 | 1,038 | 1,026 | ||||||
| Trade and other payables | 9,221 | 8,975 | 8,661 | 8,687 | 7,178 | ||||||
| Derivative financial instruments | 3 | 9 | 8 | 90 | – | ||||||
| Provisions | 916 | 1,388 | 1,095 | 1,209 | 600 | ||||||
| Income tax payable | 2,862 | 3,390 | 6,898 | 5,728 | 4,549 | ||||||
| Current liabilities | 13,903 | 15,752 | 16,787 | 17,640 | 13,320 | ||||||
| Non-current interest-bearing loans and borrowings | 9,409 | 7,338 | 9,097 | 9,137 | 10,855 | ||||||
| Deferred tax liabilities | 2,576 | 2,735 | 3,145 | 3,247 | 3,126 | ||||||
| Retirement benefit obligations | 2,265 | 2,674 | 2,472 | 3,354 | 2,732 | ||||||
| Provisions | 428 | 474 | 843 | 477 | 542 | ||||||
| Accruals | 710 | 113 | 104 | – | – | ||||||
| Other payables | 291 | 272 | 269 | 244 | 149 | ||||||
| Trade and other payables | 1,001 | 385 | 373 | 244 | 149 | ||||||
| Non-current liabilities | 15,679 | 13,606 | 15,930 | 16,459 | 17,404 | ||||||
| Total liabilities | 29,582 | 29,358 | 32,717 | 34,099 | 30,724 | ||||||
| Issued Ordinary Shares, $0.25 each | 312 | 323 | 352 | 363 | 362 | ||||||
| Redeemable Preference Shares, £1 each | – | – | – | – | – | ||||||
| Share capital | 312 | 323 | 352 | 363 | 362 | ||||||
| Share premium account | 3,504 | 3,078 | 2,672 | 2,180 | 2,046 | ||||||
| Capital redemption reserve | 153 | 139 | 107 | 94 | 94 | ||||||
| Merger reserve | 433 | 433 | 433 | 433 | 433 | ||||||
| Other reserves | 1,374 | 1,379 | 1,377 | 1,392 | 1,405 | ||||||
| Retained earnings | 17,961 | 17,894 | 18,272 | 16,198 | 11,572 | ||||||
| Capital and reserves attributable to equity holders of the Company | 23,737 | 23,246 | 23,213 | 20,660 | 15,912 | ||||||
| Non-controlling interests | 215 | 226 | 197 | 161 | 148 | ||||||
| Total equity | 23,952 | 23,472 | 23,410 | 20,821 | 16,060 | ||||||
| Total liabilities and equity | 53,534 | 52,830 | 56,127 | 54,920 | 46,784 | ||||||
| Item | Description | The company |
|---|---|---|
| Trade payables | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). | AstraZeneca PLC's trade payables declined from 2010 to 2011 but then increased from 2011 to 2012 exceeding 2010 level. |
| Current liabilities | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. | AstraZeneca PLC's current liabilities declined from 2010 to 2011 and from 2011 to 2012. |
| Non-current liabilities | Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle. | AstraZeneca PLC's non-current liabilities declined from 2010 to 2011 but then increased from 2011 to 2012 not reaching 2010 level. |
| Total liabilities | Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. | AstraZeneca PLC's total liabilities declined from 2010 to 2011 but then slightly increased from 2011 to 2012. |
| Capital and reserves attributable to equity holders of the Company | Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). | AstraZeneca PLC's capital and reserves attributable to equity holders of the Company increased from 2010 to 2011 and from 2011 to 2012. |
| Total equity | Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity. | AstraZeneca PLC's total equity increased from 2010 to 2011 and from 2011 to 2012. |
ADVERTISEMENT